Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Bioventus Inc. stock logo
BVS
Bioventus
$7.64
+7.9%
$6.80
$5.81
$14.38
$631.67M0.83399,140 shs603,873 shs
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
$3.68
+3.4%
$3.79
$1.60
$16.55
$273.29M1.17940,145 shs579,561 shs
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$80.37
$82.48
$39.40
$89.76
$3.58B1.55626,604 shsN/A
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$9.57
-0.4%
$6.79
$4.61
$9.97
$196.29M1.81168,396 shs167,703 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Bioventus Inc. stock logo
BVS
Bioventus
+7.91%+3.66%+18.08%+17.00%-16.23%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
+3.37%+1.94%-15.40%+53.97%-75.89%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
0.00%0.00%0.00%0.00%0.00%
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
-0.42%-0.62%+60.57%+76.89%+38.70%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Bioventus Inc. stock logo
BVS
Bioventus
N/AN/AN/AN/AN/AN/AN/AN/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
1.5641 of 5 stars
3.61.00.00.02.00.80.0
Cantel Medical Corp. stock logo
CMD
Cantel Medical
1.5318 of 5 stars
0.00.01.74.10.62.50.6
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
3.6347 of 5 stars
2.05.00.00.03.34.21.9
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Bioventus Inc. stock logo
BVS
Bioventus
2.75
Moderate Buy$13.7579.97% Upside
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.18
Buy$12.56241.18% Upside
Cantel Medical Corp. stock logo
CMD
Cantel Medical
0.00
N/AN/AN/A
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
4.00
Strong Buy$12.5030.62% Upside

Current Analyst Ratings Breakdown

Latest CMD, BVS, CATX, and INFU Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/22/2025
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$12.00
7/21/2025
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
Roth Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/12/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/7/2025
Bioventus Inc. stock logo
BVS
Bioventus
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$12.00
6/23/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00 ➝ $12.00
6/23/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$11.00
6/3/2025
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeOutperform ➝ Moderate Buy$15.00 ➝ $16.00
(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Bioventus Inc. stock logo
BVS
Bioventus
$564.14M1.12$0.61 per share12.58$2.80 per share2.73
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/A$2.67 per shareN/A
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$1.02B3.52$3.38 per share23.78$17.31 per share4.64
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$139.89M1.40$0.75 per share12.79$2.47 per share3.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Bioventus Inc. stock logo
BVS
Bioventus
-$156.23MN/AN/A16.61N/A-7.11%15.61%4.01%N/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
-$46.51MN/A0.00N/AN/A-4,096.66%-27.40%-23.16%11/11/2025 (Estimated)
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$13.71M$1.6569.2828.911.634.72%12.13%4.45%N/A
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
$870K$0.23159.5330.87N/A1.12%2.78%1.41%N/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Bioventus Inc. stock logo
BVS
Bioventus
N/AN/AN/AN/AN/A
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/AN/AN/AN/AN/A
Cantel Medical Corp. stock logo
CMD
Cantel Medical
$0.210.26%N/A12.73%N/A
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Bioventus Inc. stock logo
BVS
Bioventus
1.85
1.41
0.99
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
N/A
9.60
9.60
Cantel Medical Corp. stock logo
CMD
Cantel Medical
1.16
2.72
2.00
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
0.50
1.98
1.59

Institutional Ownership

CompanyInstitutional Ownership
Bioventus Inc. stock logo
BVS
Bioventus
62.94%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
54.66%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
84.13%
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
71.13%

Insider Ownership

CompanyInsider Ownership
Bioventus Inc. stock logo
BVS
Bioventus
33.00%
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
3.72%
Cantel Medical Corp. stock logo
CMD
Cantel Medical
10.70%
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
11.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
Bioventus Inc. stock logo
BVS
Bioventus
1,20082.68 million54.46 millionNot Optionable
Perspective Therapeutics, Inc. stock logo
CATX
Perspective Therapeutics
7074.26 million65.21 millionOptionable
Cantel Medical Corp. stock logo
CMD
Cantel Medical
3,66944.51 millionN/AOptionable
InfuSystem Holdings, Inc. stock logo
INFU
InfuSystem
41020.43 million19.10 millionOptionable

Recent News About These Companies

InfuSystem (NYSE:INFU) Director Sells $55,621.84 in Stock
New Strong Buy Stocks for August 8th
InfuSystem (INFU) Q2 EPS Jumps 300%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Bioventus stock logo

Bioventus NYSE:BVS

$7.64 +0.56 (+7.91%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$7.64 0.00 (-0.07%)
As of 08/22/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.

Perspective Therapeutics stock logo

Perspective Therapeutics NYSE:CATX

$3.68 +0.12 (+3.37%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$3.60 -0.08 (-2.20%)
As of 08/22/2025 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Cantel Medical stock logo

Cantel Medical NYSE:CMD

Cantel Medical Corp. provides infection prevention and control products and services for the healthcare market. The company's Medical segment offers automated endoscope reprocessing systems; disinfectants and sterilants; detergents; leak testing and manual cleaning products; storage cabinets and transport systems; manual cleaning products; endoscope process tracking products; other consumables, accessories, and supplies for use in disinfect rigid endoscopes, flexible endoscopes, and other instrumentation; and technical maintenance services. Its Life Sciences segment provides dialysis water purification and bicarbonate mixing systems; hollow fiber filters, and other filtration and separation products; liquid disinfectants and cold sterilization products; dry fog products; room temperature sterilization equipment and services; and clean-room certification and decontamination services for the dialysis and other healthcare, research laboratories, food and beverage, and commercial industrial customers, as well as microbiological testing services. The company's Dental segment offers hand and powered dental instruments, instrument reprocessing and sterility assurance products, towels, bibs, tray liners, sponges, nitrous oxide/oxygen sedation equipment and related single-use disposable nasal masks, face masks, and shields. It also provides hand sanitizers, germicidal wipes, disinfectants, surface disinfectants, waterline treatment products, saliva ejectors, evacuator tips, plastic cups, prophy angles, and prophy paste. The company's Dialysis segment provides hemodialysis concentrates and other ancillary supplies; medical device reprocessing systems; and sterilants and disinfectants. The company sells its products through its direct distribution network in the United States; and directly or under various third-party distribution agreements internationally. Cantel Medical Corp. was founded in 1963 and is headquartered in Little Falls, New Jersey.

InfuSystem stock logo

InfuSystem NYSE:INFU

$9.57 -0.04 (-0.42%)
Closing price 08/22/2025 04:00 PM Eastern
Extended Trading
$9.57 0.00 (0.00%)
As of 08/22/2025 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.